<DOC>
	<DOCNO>NCT01605734</DOCNO>
	<brief_summary>TACE widely use patient unresectable HCC . However , non-curative approach ; thus , strategy improve survival patient need . Sorafenib regard standard treatment advance HCC . It first systemic therapy demonstrate significant survival benefit HCC patients.The hypothesis combination TACE sorafenib could improve survival patient unresectable HCC .</brief_summary>
	<brief_title>TACE Combinated With Sorafenib Treating Patients With Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients newly diagnose HCC accord European Association Study Liver criterion . BCLC stage B C ChildPugh class score≤8 ECOG performance status ≤2 Etiology : Hepatitis B virus ( HBV ) infection Written inform consent ( approved Institutional Review Board [ IRB ] obtain prior study specific screen procedure Patient must able comply protocol Age 1875 year Haematology : Absolute neutrophil count ( ANC ) &gt; 1.5 x 109/L , Platelet count &gt; 50 x 109/L , Haemoglobin &gt; 9 g/dL ( may transfuse maintain exceed level ) Prothrombin time international normalized ratio &lt; 1.5 Biochemistry : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5 x upper limit normal , Total bilirubin &lt; 3 x upper limit normal , Serum creatinine &lt; 1.5 x upper limit normal , Cholinesterase &gt; 0.5x low limit normal，Prealbumin &gt; 0.5x low limit normal . Life expectancy &gt; 3 month BCLC stage D ChildPugh Score≥9 Clinically severe gastrointestinal bleeding within 4 week start treatment Preexisting history hepatic encephalopathy uncontrolled hypertension Pregnancy ( positive serum pregnancy test ) lactation Serious , nonhealing wound , ulcer , bone fracture Currently recent ( within 30 day prior start study treatment ) treatment another investigational drug participation another investigational study Clinically significant ( i.e . active ) cardiovascular disease example cerebrovascular accident ( ≤ 6 month prior study entry ) , myocardial infarction ( ≤ 6 month prior study entry ) , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication Evidence disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use Sorafenib/TACE patient high risk treatment complication Other severe concomitant disease may reduce life expectancy Risk allergic reaction study drug Drug abuse physical , psychological , social problem may interfere participation study evaluation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>transarterial chemoembolization</keyword>
	<keyword>sorafenib</keyword>
</DOC>